Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Temozolomide plus short-course radiotherapy versus short-course radiotherapy alone in elderly patients with newly diagnosed glioblastoma
NL-OMON39213Phase 3Active, not recruiting
- Sponsor
- European Organisation for Research and Treatment of Cancer
- Start
- Nov 2009
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of temozolomide in glioblastoma (GBM) (2 arms), sponsored by European Organisation for Research and Treatment of Cancer. Primary endpoint: overall survival. Started Nov 2009; status: active, not recruiting.
02
Drugs
temozolomide
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NL-OMON39213.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON39213.